Abu Elhassan Usama, Al-Mani Salihah Y, Alqahtani Saad M A, Elnamaky Medhat, Alfaifi Abdulaziz, Alshehri Mohammed A, Alasiri Haneen A, Kadasah Ali S, Musleh Abdullah, Alshafa Fawwaz A, Qureshi Muhammad S S, Assiri Abdulmohsen Y, Falqi Abdulrahman I, Asiri Bader I, Ahmed Haider M O, Alshehry Saleem, Abdalla Abdelrahman M
Assistant Professor of Pulmonary Medicine, Department of Pulmonary Medicine, Faculty of Medicine, Cairo University, Cairo, Egypt. Consultant of Pulmonary Medicine, Department of Internal Medicine, Armed Forces Hospital Southern Region (AFHSR), Khamis Mushayt, Saudi Arabia.
Department of Internal Medicine, Armed Forces Hospital Southern Region (AFHSR), Khamis Mushayt, Saudi Arabia.
Multidiscip Respir Med. 2024 Sep 9;19(1):985. doi: 10.5826/mrm.2024.985.
Abstract Background: Few studies have addressed the effects of biological therapies on laboratory outcomes and changes in FEV1 in patients with severe asthma (SA) and chronic rhinosinusitis (CRS). We aimed to study the effect of three biological therapies on laboratory outcomes and FEV1 in Saudi Arabian patients with SA and CRS.
From March to September 2022, a retrospective observational cohort study was undertaken at the severe asthma clinics of the Armed Forces Hospital-Southern Region (AFHSR) and King Khalid University Hospital, Abha, Saudi Arabia, to delineate the effects of 3 biological therapies (benralizumab, dupilumab, and omalizumab) in adults with SA and concomitant CRS in terms of FEV1 and laboratory parameters (serum IgE and eosinophilic counts).
Eighty patients were enrolled, with a mean age of 46.68. There were 45 (56%) females and 35 (44%) males. There were significant improvements in FEV1 and laboratory parameters (serum IgE and eosinophilic counts) after 6 &12 months of biological therapies compared to pre-biological therapies (p<0.001, each). The response was different among different biological therapies. The improvements in FEV1, serum IgE, and eosinophilic counts were manifest with benralizumab and dupilumab but not with omalizumab.
Results from the first study from two large Saudi Arabian tertiary centers for patients with severe asthma and chronic rhinosinusitis agree with and support those of worldwide real-life ones. One-year follow-up of patients with SA and CRS showed the effectiveness of benralizumab and dupilumab, but not omalizumab, regarding FEV1, serum IgE, and eosinophilic counts. Further prospective multicenter studies are warranted.
摘要背景：很少有研究探讨生物疗法对重度哮喘（SA）和慢性鼻-鼻窦炎（CRS）患者实验室检查结果及第一秒用力呼气容积（FEV1）变化的影响。我们旨在研究三种生物疗法对沙特阿拉伯SA和CRS患者实验室检查结果及FEV1的影响。
2022年3月至9月，在沙特阿拉伯南部地区武装部队医院（AFHSR）和阿卜哈国王哈立德大学医院的重度哮喘诊所进行了一项回顾性观察队列研究，以阐明三种生物疗法（贝那利珠单抗、度普利尤单抗和奥马珠单抗）对合并CRS的SA成年患者FEV1和实验室参数（血清IgE和嗜酸性粒细胞计数）的影响。
共纳入80例患者，平均年龄46.68岁。其中女性45例（56%），男性35例（44%）。与生物疗法治疗前相比，生物疗法治疗6个月和12个月后，FEV1和实验室参数（血清IgE和嗜酸性粒细胞计数）有显著改善（均p<0.001）。不同生物疗法的反应有所不同。贝那利珠单抗和度普利尤单抗可使FEV1、血清IgE和嗜酸性粒细胞计数得到改善，但奥马珠单抗未显示此效果。
来自沙特阿拉伯两个大型三级中心的首项针对重度哮喘和慢性鼻-鼻窦炎患者的研究结果与全球实际研究结果一致并相互支持。对SA和CRS患者进行的一年随访显示，就FEV1、血清IgE和嗜酸性粒细胞计数而言，贝那利珠单抗和度普利尤单抗有效，但奥马珠单抗无效。有必要开展进一步的前瞻性多中心研究。
